Leucovorin and 5-FU

DRUG3 trials

Sponsors

Kaohsiung Medical University Chung-Ho Memorial Hospital, Akeso, Gruppo Oncologico del Nord-Ovest

Conditions

Colorectal AdenocarcinomaColorectal CancerMetastatic Colorectal Cancer

Phase 2

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Kaohsiung Medical University Chung-Ho Memorial HospitalMetastatic Colorectal Cancer

Start: 2019-02-26End: 2021-12-31Target: 153Updated: 2019-03-21

Phase 3

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

RecruitingNCT06951503

AkesoColorectal Adenocarcinoma

Start: 2025-05-27End: 2029-01-07Target: 560Updated: 2026-03-04

Phase 4

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Not yet recruitingNCT07094893

Gruppo Oncologico del Nord-OvestColorectal Cancer

Start: 2026-04-15End: 2030-03-31Target: 280Updated: 2026-01-14

Related Papers

Efficacy and safety of regorafenib plus FOLFIRI with <i>UGT1A1</i> genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter, phase II, open-label, two-arm randomized controlled tria.

2025-10-23

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

Trials2019-12-018 citations